RIGL
Rigel Pharmaceuticals, Inc.
Biotechnology
Market Cap$485M
5Y Perf.+34.2%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
RIGL vs PTCT vs FOLD vs RARE
Revenue, margins, valuation, and 5-year total return — side by side.
PTCT
PTC Therapeutics, Inc.
Biotechnology
Market Cap$5.35B
5Y Perf.+27.2%
FOLD
Amicus Therapeutics, Inc.
Biotechnology
Market Cap$4.55B
5Y Perf.+15.9%
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.57B
5Y Perf.-61.8%
RIGL vs PTCT vs FOLD vs RARE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RIGL | PTCT | FOLD | RARE |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $485M | $5.35B | $4.55B | $2.57B |
| Revenue (TTM) | $300M | $827M | $634M | $669M |
| Net Income (TTM) | $364M | $-187M | $-27M | $-609M |
| Gross Margin | 93.4% | 49.7% | 87.9% | 83.6% |
| Operating Margin | 41.6% | -8.3% | 5.2% | -83.9% |
| Forward P/E | 6.0x | 8.3x | 40.6x | — |
| Total Debt | $53M | $492M | $483M | $1.28B |
| Cash & Equiv. | $41M | $985M | $214M | $434M |
RIGL vs PTCT vs FOLD vs RARE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RIGL
PTCT
FOLD
RARE
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Rigel Pharmaceutica… (RIGL) | 100 | 134.2 | +34.2% |
| PTC Therapeutics, I… (PTCT) | 100 | 127.2 | +27.2% |
| Amicus Therapeutics… (FOLD) | 100 | 115.9 | +15.9% |
| Ultragenyx Pharmace… (RARE) | 100 | 38.2 | -61.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RIGL vs PTCT vs FOLD vs RARE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RIGL leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Amicus Therapeutics, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. PTCT also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
RIGL
Rigel Pharmaceuticals, Inc.
The Value Play
RIGL carries the broadest edge in this set and is the clearest fit for value and quality.
- Better valuation composite
- 121.5% margin vs RARE's -91.0%
- 99.3% ROA vs RARE's -45.8%, ROIC 45.8% vs -89.4%
Best for: value and quality
PTCT
PTC Therapeutics, Inc.
The Growth Play
PTCT is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 114.5%, EPS growth 264.5%, 3Y rev CAGR 35.3%
- 7.3% 10Y total return vs FOLD's 119.2%
- 114.5% revenue growth vs FOLD's 20.0%
Best for: growth exposure and long-term compounding
FOLD
Amicus Therapeutics, Inc.
The Income Pick
FOLD is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- beta 0.63
- Lower volatility, beta 0.63, current ratio 2.84x
- Beta 0.63, current ratio 2.84x
- Beta 0.63 vs RARE's 1.42
Best for: income & stability and sleep-well-at-night
RARE
Ultragenyx Pharmaceutical Inc.
The Growth Angle
RARE lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PTCT | 114.5% revenue growth vs FOLD's 20.0% |
| Value | RIGL | Better valuation composite |
| Quality / Margins | RIGL | 121.5% margin vs RARE's -91.0% |
| Stability / Safety | FOLD | Beta 0.63 vs RARE's 1.42 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | FOLD | +137.9% vs RARE's -21.8% |
| Efficiency (ROA) | RIGL | 99.3% ROA vs RARE's -45.8%, ROIC 45.8% vs -89.4% |
RIGL vs PTCT vs FOLD vs RARE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
Segment breakdown not available.
FY 2025
RIGL vs PTCT vs FOLD vs RARE — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRIGLLAGGINGRARE
Who Leads Where
RIGL leads in 3 of 6 categories
FOLD leads 1 • PTCT leads 0 • RARE leads 0 • 1 tied
Explore the data ↓RAREUltragenyx Pharmaceut…
0leads
PTCTPTC Therapeutics, Inc.
0leads
FOLDAmicus Therapeutics, …
1leads
RIGLRigel Pharmaceuticals…
3leads
6 Total Categories
CATEGORYLEADERvs FOLDvs PTCTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
RIGL4/6
Valuation MetricsMultiples, price ratios, and targets
RIGL5/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
RIGL6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
FOLD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
RIGL leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PTCT is the larger business by revenue, generating $827M annually — 2.8x RIGL's $300M. RIGL is the more profitable business, keeping 121.5% of every revenue dollar as net income compared to RARE's -91.0%. On growth, FOLD holds the edge at +23.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | RIGLRigel Pharmaceuti… | PTCTPTC Therapeutics,… | FOLDAmicus Therapeuti… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $300M | $827M | $634M | $669M |
| EBITDAEarnings before interest/tax | $126M | -$37M | $40M | -$536M |
| Net IncomeAfter-tax profit | $364M | -$187M | -$27M | -$609M |
| Free Cash FlowCash after capex | $79M | -$229M | $30M | -$487M |
| Gross MarginGross profit ÷ Revenue | +93.4% | +49.7% | +87.9% | +83.6% |
| Operating MarginEBIT ÷ Revenue | +41.6% | -8.3% | +5.2% | -83.9% |
| Net MarginNet income ÷ Revenue | +121.5% | -22.6% | -4.3% | -91.0% |
| FCF MarginFCF ÷ Revenue | +26.4% | -27.7% | +4.7% | -72.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +10.3% | -76.8% | +23.7% | -2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -30.2% | -100.3% | -89.0% | -17.2% |
RIGL leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
RIGL leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
At 1.3x trailing earnings, RIGL trades at a 84% valuation discount to PTCT's 8.3x P/E. On an enterprise value basis, RIGL's 3.9x EV/EBITDA is more attractive than FOLD's 114.9x.
| Metric | RIGLRigel Pharmaceuti… | PTCTPTC Therapeutics,… | FOLDAmicus Therapeuti… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| Market CapShares × price | $485M | $5.3B | $4.5B | $2.6B |
| Enterprise ValueMkt cap + debt − cash | $498M | $4.9B | $4.8B | $3.4B |
| Trailing P/EPrice ÷ TTM EPS | 1.35x | 8.29x | -164.85x | -4.48x |
| Forward P/EPrice ÷ next-FY EPS est. | 6.04x | — | 40.62x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 3.90x | 5.42x | 114.88x | — |
| Price / SalesMarket cap ÷ Revenue | 1.65x | 3.09x | 7.17x | 3.82x |
| Price / BookPrice ÷ Book value/share | 1.26x | — | 16.29x | — |
| Price / FCFMarket cap ÷ FCF | 6.42x | 7.61x | 152.43x | — |
RIGL leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
RIGL leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
RIGL delivers a 147.0% return on equity — every $100 of shareholder capital generates $147 in annual profit, vs $-6 for RARE. RIGL carries lower financial leverage with a 0.14x debt-to-equity ratio, signaling a more conservative balance sheet compared to FOLD's 1.76x. On the Piotroski fundamental quality scale (0–9), PTCT scores 7/9 vs RARE's 4/9, reflecting strong financial health.
| Metric | RIGLRigel Pharmaceuti… | PTCTPTC Therapeutics,… | FOLDAmicus Therapeuti… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | +147.0% | — | -12.0% | -6.1% |
| ROA (TTM)Return on assets | +99.3% | -6.8% | -3.2% | -45.8% |
| ROICReturn on invested capital | +45.8% | — | +5.3% | -89.4% |
| ROCEReturn on capital employed | +48.7% | +55.9% | +5.1% | -46.4% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 7 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.14x | — | 1.76x | — |
| Net DebtTotal debt minus cash | $13M | -$492M | $269M | $842M |
| Cash & Equiv.Liquid assets | $41M | $985M | $214M | $434M |
| Total DebtShort + long-term debt | $53M | $492M | $483M | $1.3B |
| Interest CoverageEBIT ÷ Interest expense | 30.74x | -1.67x | 1.00x | -14.49x |
RIGL leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — RIGL and PTCT each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PTCT five years ago would be worth $16,026 today (with dividends reinvested), compared to $2,281 for RARE. Over the past 12 months, FOLD leads with a +137.9% total return vs RARE's -21.8%. The 3-year compound annual growth rate (CAGR) favors RIGL at 30.2% vs RARE's -17.8% — a key indicator of consistent wealth creation.
| Metric | RIGLRigel Pharmaceuti… | PTCTPTC Therapeutics,… | FOLDAmicus Therapeuti… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -37.3% | -16.0% | +1.5% | +10.7% |
| 1-Year ReturnPast 12 months | +42.1% | +58.2% | +137.9% | -21.8% |
| 3-Year ReturnCumulative with dividends | +120.5% | +16.1% | +19.0% | -44.5% |
| 5-Year ReturnCumulative with dividends | -22.4% | +60.3% | +48.6% | -77.2% |
| 10-Year ReturnCumulative with dividends | +7.1% | +733.2% | +119.2% | -59.4% |
| CAGR (3Y)Annualised 3-year return | +30.2% | +5.1% | +6.0% | -17.8% |
Evenly matched — RIGL and PTCT each lead in 2 of 6 comparable metrics.
Risk & Volatility
FOLD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
FOLD is the less volatile stock with a 0.63 beta — it tends to amplify market swings less than RARE's 1.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FOLD currently trades 99.9% from its 52-week high vs RIGL's 50.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RIGLRigel Pharmaceuti… | PTCTPTC Therapeutics,… | FOLDAmicus Therapeuti… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.03x | 1.13x | 0.63x | 1.42x |
| 52-Week HighHighest price in past year | $52.24 | $87.50 | $14.50 | $42.37 |
| 52-Week LowLowest price in past year | $16.88 | $37.94 | $5.51 | $18.29 |
| % of 52W HighCurrent price vs 52-week peak | +50.2% | +73.7% | +99.9% | +61.7% |
| RSI (14)Momentum oscillator 0–100 | 34.0 | 45.3 | 72.2 | 66.6 |
| Avg Volume (50D)Average daily shares traded | 361K | 1.0M | 3.0M | 1.8M |
FOLD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: RIGL as "Buy", PTCT as "Buy", FOLD as "Buy", RARE as "Buy". Consensus price targets imply 97.1% upside for RARE (target: $52) vs 0.1% for FOLD (target: $15).
| Metric | RIGLRigel Pharmaceuti… | PTCTPTC Therapeutics,… | FOLDAmicus Therapeuti… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $40.00 | $89.67 | $14.50 | $51.50 |
| # AnalystsCovering analysts | 15 | 26 | 24 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | 1 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RIGL leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). FOLD leads in 1 (Risk & Volatility). 1 tied.
Best OverallRigel Pharmaceuticals, Inc. (RIGL)Leads 3 of 6 categories
Loading custom metrics...
RIGL vs PTCT vs FOLD vs RARE: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is RIGL or PTCT or FOLD or RARE a better buy right now?
For growth investors, PTC Therapeutics, Inc.
(PTCT) is the stronger pick with 114. 5% revenue growth year-over-year, versus 20. 0% for Amicus Therapeutics, Inc. (FOLD). Rigel Pharmaceuticals, Inc. (RIGL) offers the better valuation at 1. 3x trailing P/E (6. 0x forward), making it the more compelling value choice. Analysts rate Rigel Pharmaceuticals, Inc. (RIGL) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — RIGL or PTCT or FOLD or RARE?
On trailing P/E, Rigel Pharmaceuticals, Inc.
(RIGL) is the cheapest at 1. 3x versus PTC Therapeutics, Inc. at 8. 3x. On forward P/E, Rigel Pharmaceuticals, Inc. is actually cheaper at 6. 0x.
03Which is the better long-term investment — RIGL or PTCT or FOLD or RARE?
Over the past 5 years, PTC Therapeutics, Inc.
(PTCT) delivered a total return of +60. 3%, compared to -77. 2% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: PTCT returned +733. 2% versus RARE's -59. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — RIGL or PTCT or FOLD or RARE?
By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.
(FOLD) is the lower-risk stock at 0. 63β versus Ultragenyx Pharmaceutical Inc. 's 1. 42β — meaning RARE is approximately 125% more volatile than FOLD relative to the S&P 500. On balance sheet safety, Rigel Pharmaceuticals, Inc. (RIGL) carries a lower debt/equity ratio of 14% versus 176% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — RIGL or PTCT or FOLD or RARE?
By revenue growth (latest reported year), PTC Therapeutics, Inc.
(PTCT) is pulling ahead at 114. 5% versus 20. 0% for Amicus Therapeutics, Inc. (FOLD). On earnings-per-share growth, the picture is similar: Rigel Pharmaceuticals, Inc. grew EPS 1868% year-over-year, compared to 7. 3% for Ultragenyx Pharmaceutical Inc.. Over a 3-year CAGR, PTCT leads at 35. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — RIGL or PTCT or FOLD or RARE?
Rigel Pharmaceuticals, Inc.
(RIGL) is the more profitable company, earning 124. 7% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 124. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PTCT leads at 49. 5% versus -79. 5% for RARE. At the gross margin level — before operating expenses — PTCT leads at 95. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is RIGL or PTCT or FOLD or RARE more undervalued right now?
On forward earnings alone, Rigel Pharmaceuticals, Inc.
(RIGL) trades at 6. 0x forward P/E versus 40. 6x for Amicus Therapeutics, Inc. — 34. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RARE: 97. 1% to $51. 50.
08Which pays a better dividend — RIGL or PTCT or FOLD or RARE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is RIGL or PTCT or FOLD or RARE better for a retirement portfolio?
For long-horizon retirement investors, Amicus Therapeutics, Inc.
(FOLD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 63), +119. 2% 10Y return). Both have compounded well over 10 years (FOLD: +119. 2%, RARE: -59. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between RIGL and PTCT and FOLD and RARE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(RIGL: 10.3% · PTCT: -76.8%)P/E Ratio<
x
(RIGL: 1.3x · PTCT: 8.3x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.